Real-world study of xeligekimab for moderate to severe psoriasis
Treatments studied
Part of Bones, joints & muscles, Skin clinical trials.
This study looks at how well xeligekimab works for people with moderate to severe plaque psoriasis in everyday medical practice. It may help you if you are about to start this treatment for the first time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with moderate to severe plaque psoriasis.
- Your doctor has decided that xeligekimab is a good treatment option for you and you have not received it before.
- You are willing to sign a consent form agreeing to participate.
- You do not have psoriasis caused by certain medications (like beta-blockers or lithium).
- You are not allergic to xeligekimab or any of its ingredients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental oral medication (a TYK2 inhibitor) for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing psoriasis symptoms.
This study looks at how well ixekizumab (an injection medication) works for moderate-to-severe plaque psoriasis, and what happens when the treatment is withdrawn. It may help you learn whether stopping the medicine is safe and how skin disease outcomes change over time.
This study tests an experimental drug, SHR-1139, given as an injection, to see if it can help people with plaque psoriasis who haven't gotten enough relief from other biologic treatments. It aims to improve skin symptoms and quality of life.
This trial tests an injectable drug, QL2106, for people with moderate to severe plaque psoriasis. It may help if you are a candidate for light therapy or other systemic treatments.
This study tests a new oral pill (HSK47388) for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective in reducing the severity and area of psoriasis over 12 weeks.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.